DName-iT (“the Company”) is excited to announce that in December 2024 the EU patent office gave notice of its intention to grant the Company’s 2017 patent EP345 8606, providing important protections for DNames™ in broad use. Further good news was received in early January of this year when the US Patent Office also indicated they intend to grant the 2017 patent application 16/302,345.    These developments mark a significant step forward for DName-iT as it continues to expand

DName-iT Holdings Limited (or ‘the Company’), backed by EMV Capital plc, is proud to announce that its DName™ platform has achieved Class 1 medical device registration in both the UK and EU. These registrations mark a milestone moment for the Company, as it means DNames™ and their companion DName-iT software can be marketed and sold in two important regions.    The DName™ platform is the Company’s proprietary technology that has been developed for use in the $13.5Bn (2024 est

DName-iT Holdings Limited (“DName-iT” or the “Company”) Dname-iT raises £500,000 from EMV Capital and KU Leuven’s Gemma Frisius Fund to scale-up its ground-breaking verification platform for NGS Laboratories. DName-iT is delighted to announce that EMV Capital (“EMVC”), the VC investor specialising in early-stage high-growth deep tech companies, has led a new £500,000 investment into DName-iT, supported by EMV Capital investor network and the Gemma Frisius Fund, a venture se

NetScientific announces investment in DName-iT bringing important improvements to diagnostic Next Generation Sequencing 7th January 2015: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced its investment in DName-iT NV ("DName-iT") a spin-out from KU Leuven in Belgium As a subsidiary company of NetScientific, DName-iT is developing a "solution of choice" for improving the quality and workflow of genetic diagnostic tests based on next